ProfileGDS5678 / 1420406_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 63% 63% 61% 63% 67% 66% 63% 62% 65% 63% 63% 65% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9395565
GSM967853U87-EV human glioblastoma xenograft - Control 23.7746863
GSM967854U87-EV human glioblastoma xenograft - Control 33.7475363
GSM967855U87-EV human glioblastoma xenograft - Control 43.63361
GSM967856U87-EV human glioblastoma xenograft - Control 53.7650563
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0789867
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0085566
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.788763
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6794362
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8793265
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7943863
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7406563
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8926765
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8029464